• Investment World
• eWorld
• Brand Line
• Mentor
• Life
• Brand Quest
• The New Manager

Stocks

• Quotes
• SE Diary
• Scoreboard
• Open-End Mutual Fund

Cross Currency

• Rates
  
  

Shipping

• Ports
  
  

Archives

• Yesterday
• Datewise
• Resources
• In Focus
• In Depth

Group Sites

• The Hindu
• The Hindu ePaper
• Business Line
• Business Line ePaper
• Sportstar
• Frontline
• The Hindu eBooks
• The Hindu Images

Our Bureau

Mumbai, Dec 4 The Netherlands-based multi-speciality company DSM has entered into a manufacturing agreement with Mumbai-based Arch Pharmalabs to make generic active pharmaceutical ingredients (API).

The agreement builds on a relationship that Arch Pharmalabs forged when it started eight years ago – DSM was its first and key customer. The manufacturing deal would also strengthen DSM’s generics portfolio of innovation molecules that targets $1 billion sales by 2010.

DSM Anti Infectives (DAI), a wholly owned subsidiary of the $11 billion DSM Group, will provide the patented technology to Arch Pharma for further development of non-infringing processes, said Mr Hans Van Nistelrooij, DAI’s Vice-President. While DSM’s portfolio predominantly consists of anti-infectives, the agreement seeks to broaden the technology to other areas like cardio-vascular, immuno-suppressants and statins, he said. The deal will also support DSM’s global customer base, he added.

More Stories on : Alliances & Joint Ventures | Pharmaceuticals

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page

Stories in this Section
Nicholas’ drug trial plan on expected lines

Copyright © 2007, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line